Inhibrx Biosciences, Inc. (INBX)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralKlinisches Biotechunternehmen ohne KI-Produkt und ohne KI-Umsatz; künstliche Intelligenz taucht in den geprüften Filings nur als beiläufiger Hinweis auf, dass Mitarbeiter generative KI-Werkzeuge nutzen dürfen — eingebettet in ein Geschäftsgeheimnis-Risiko, nicht als Geschäftsmodell oder wesentliches Risiko.
View the full file — quotes, sources, reviewed filings
„Our employees can use generative artificial intelligence ("AI") technologies in certain circumstances to perform portions of their work. There can be no assurance that employees will not inadvertently or improperly input information that is proprietary, confidential, or sensitive, including trade secrets, into AI systems in a manner that results in unauthorized disclosure or loss of confidentiality."
Unsere Mitarbeiter dürfen unter bestimmten Umständen generative Technologien der künstlichen Intelligenz („KI“) einsetzen, um Teile ihrer Arbeit zu erledigen. Es kann nicht zugesichert werden, dass Mitarbeiter nicht versehentlich oder unsachgemäß geschützte, vertrauliche oder sensible Informationen – einschließlich Geschäftsgeheimnissen – so in KI-Systeme eingeben, dass es zu einer unbefugten Offenlegung oder zum Verlust der Vertraulichkeit kommt.
„We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms."
Wir sind ein Biopharma-Unternehmen im klinischen Stadium mit einer Pipeline neuartiger biologischer Wirkstoffkandidaten, die mithilfe unserer firmeneigenen modularen Protein-Engineering-Plattformen entwickelt werden.
Filings Reviewed: 10-K 2026-03-19 · 10-K 2025-03-17 · 10-Q 2026-05-14 · 10-Q 2025-11-14 · 10-Q 2025-08-13 · 10-Q 2025-05-14
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -3.31 | – | 0 | -93.90 | -47,865.00 | -44 | -44 |
| 2025: Q1 | -2.80 | – | 0 | – | – | -36 | -36 |
| 2025: Q2 | -1.85 | -101.50 | 1 | 1,200.00 | -2,204.20 | -30 | -30 |
| 2025: Q3 | -2.28 | – | 0 | – | – | -34 | -34 |
| 2025: Q4 | -2.12 | – | 0 | -100.00 | – | -30 | -30 |
| 2026: Q1 | -2.15 | – | 0 | – | – | -38 | -38 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Inhibrx Biosciences, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, beschäftigt sich mit der Entwicklung biologischer Therapeutika für Menschen mit lebensbedrohlichen Erkrankungen.
| Employees | 109 |
|---|---|
| Headquarters | La Jolla, CA |
| Website | inhibrx.com |
| IPO Date | 29. May 2024 |
| Next Earnings | 12. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark Paul Lappe | Founder, CEO & Chairman | 1967 |
| David J. Matly M.B.A. | President | 1986 |
| Kelly Devine Deck B.S., CPA, M.S. | Executive VP, CFO & Treasurer | 1980 |
| Bonne Adams M.B.A. | Vice President of Operations | 1977 |
| Kate Burke CPA, M.B.A. | Vice President of Accounting | – |
| Ashraf Amanullah Ph.D. | Executive VP & Chief Technical Operations Officer | 1968 |
| Carlos Bais Ph.D. | EVP & Chief Scientific Officer | – |
| Leah Pollema J.D. | VP, General Counsel & Corporate Secretary | – |
| Josep Garcia Ph.D. | Executive VP & Chief Clinical Development Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.